Cosmos Health Expands E-Commerce Subscription Operations Across Oceania
Cosmos Health has extended its online purchasing and recurring-delivery model to Australia, New Zealand and the broader Oceania region, using the platform behind its U.S. operations.
Cosmos Health Inc. (NASDAQ:COSM) has expanded its e-commerce and subscription operations into Australia, New Zealand and the broader Oceania region. The company said customers can already place orders through its online stores, with recurring delivery available during checkout.
The company’s products are available online across the stated Oceania markets, and sales have begun. Customers can either make individual purchases or select a subscription option for repeat deliveries.
Cosmos Health said the regional service uses the same platform that supports its United States direct-to-consumer business. The company presented the expansion as part of its effort to extend its subscription model into additional international markets.
Cosmos Health described Australia and New Zealand as multibillion-dollar and growing health and wellness markets. It cited consumer interest in preventive health and nutritional supplements, high spending power and widespread online-shopping adoption.
As of October 19, 2026, the company reported 8,940 active subscriptions and 14,624 online checkout orders in its U.S. direct-to-consumer business. The company said the Oceania expansion follows growth in that operation.
Cosmos Health said it intends to continue assessing additional international markets for its direct-to-consumer subscription model. Chief Executive Officer Greg Siokas described Oceania as an additional step in the company’s international expansion and said Cosmos Health would continue focusing on customer retention and disciplined growth.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group. Its portfolio includes pharmaceutical and nutraceutical brands such as Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub.
Through its subsidiary Cana Laboratories S.A., the company manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in the European Union. Its subsidiaries in Greece and the UK distribute pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter medicines. Cosmos Health also has research and development activities and operates in telehealth through its acquisition of ZipDoctor, Inc.
Cosmos Health cautioned that statements about future plans and performance are subject to risks and uncertainties. These include obtaining financing, developing and commercialising proprietary products and technologies, operating in international markets, regulatory and legal changes, foreign-exchange and interest-rate movements, inflation, litigation, insurance coverage and the timing and cost of capital investments.
The company also identified risks related to digital-asset strategies, potential asset-backed or tokenised financing programmes, contract-manufacturing volumes, gross margins, order timing and other factors that could cause actual results to differ materially from its expectations.
Cosmos Health announced that its e-commerce and subscription business is now live across Australia, New Zealand and the broader Oceania region, with sales already underway. Customers can buy Cosmos Health products through the company’s online stores and select recurring delivery at checkout.
Cosmos Health announced the expansion on October 22, 2026. The announcement covers the launch of its e-commerce and subscription business across Australia, New Zealand and the broader Oceania region.
Cosmos Health’s business is operating across Australia, New Zealand and the broader Oceania region. The company said customers in those markets can purchase its products online, with subscription delivery available at checkout.
Cosmos Health allows customers in Oceania to purchase products through its online stores and opt for recurring delivery at checkout. The company said sales in the region are already underway.
Cosmos Health described Australia and New Zealand as multibillion-dollar and growing health and wellness markets. The company cited interest in preventive health and nutritional supplements, high spending power and widespread online-shopping adoption as conditions supporting direct-to-consumer and subscription-based models.
Cosmos Health reported 8,940 active subscriptions and 14,624 online checkout orders in its US direct-to-consumer business as of October 19, 2026. The company said the Oceania expansion follows strong growth in that US business.
Cosmos Health said the Oceania business is powered by the same platform behind its growth in the United States. The company is using that platform for online product purchases and recurring delivery subscriptions in the region.
Cosmos Health said it intends to continue evaluating additional international markets for its direct-to-consumer subscription model. The company described Oceania as the next step in building a global, recurring customer base.
Greg Siokas said Cosmos Health’s subscription model had attracted thousands of US customers who receive products on a recurring basis, and that the same model is now live in Australia, New Zealand and the broader Oceania region. He said the company intends to keep expanding its reach while focusing on customer retention and disciplined growth.
Cosmos Health describes itself as a diversified, vertically integrated global healthcare group with proprietary pharmaceutical and nutraceutical brands. Through its subsidiaries, it manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in the European Union, distributes pharmaceuticals and parapharmaceuticals in Greece and the UK, and has activities in research and development and telehealth.
Cosmos Health is identified in the announcement as trading on NASDAQ under the ticker NASDAQ:COSM. In the company description, the listing is also written as NASDAQ: COSM.
Cosmos Health said its forward-looking statements involve risks including raising sufficient financing, developing and commercialising proprietary products and technologies, operating in international markets, regulatory and legal changes, foreign-exchange and interest-rate changes, inflation, litigation, insurance coverage and planned capital investments. The company also cited risks linked to digital-asset strategies, potential asset-backed or tokenised financing programmes, contract-manufacturing volumes, gross margins and the timing of orders, and warned that actual results could differ materially from its expectations.